Thursday, November 17, 2011
Bionovo Inc., of Emeryville, Calif., reported that the first patient was randomized and will begin dosing in a Phase III pivotal trial evaluating the safety and efficacy of two doses (5 g/day and 10 g/day) of Menerba (MF101) in 1,200 postmenopausal women for the treatment of menopausal hot flashes. Efficacy will be measured by the reduction of moderate to severe hot flushes from baseline to 12 weeks of treatment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.